The Claim
Inhibition of TAS1R3 does not alter the phosphorylation or expression levels of IRS1 and AKT in human skeletal muscle cells, indicating that TAS1R3-mediated glucose uptake occurs independently of the canonical insulin signaling pathway.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Blocking the TAS1R3 protein in human muscle cells does not change the activity of IRS1 and AKT, two key proteins in the insulin signaling pathway, meaning TAS1R3 affects glucose uptake through a different mechanism than insulin.
See the scientific wording
TAS1R3 inhibition does not affect canonical insulin signaling components IRS1 and AKT in human skeletal muscle cells, suggesting its role in glucose uptake is independent of the classical insulin pathway.
When TAS1R3 detects nutrients in muscle cells, it activates a protein called Rac1, which changes the structure of the cell's internal skeleton. This change allows glucose transporters to move to the cell surface, letting glucose enter the cell without using the insulin pathway that involves IRS1 and AKT.
What the research says
1 studyStudy: TAS1R3 Regulates GTPase Signaling in Human Skeletal Muscle Cells for Glucose Uptake
Blocking TAS1R3 slows down glucose uptake in muscle cells, but it doesn’t mess with the usual insulin signal (IRS1 and AKT). That means it works through a different, backup pathway.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.